Outram Bio

Outram Bio targets early-stage life sciences and biotechnology companies, primarily at the startup and Series A stages. The firm's mandate covers drug discovery, platform technologies, and therapeutic development. This singular focus on biotech distinguishes it from generalist technology and healthcare funds active in Asia.

As a Singapore-based firm with a pure-play life science mandate, Outram Bio likely sources deal flow through direct engagement with academic research institutions, technology transfer offices, and entrepreneurial scientists across Asia's biotechnology hubs. The firm's dedicated sector focus provides specialized access to deep-science opportunities that generalist funds may overlook, though its specific sourcing network is not publicly detailed.

Outram Bio structures its investments primarily as direct equity positions in early-stage life science companies. There is no public record of the firm operating as a fund-of-funds or participating in external blind-pool commitments. The firm's model appears centered on direct venture-stage dealmaking.

Outram Bio is structured as an asset manager and private equity firm, not a family office. It operates with a venture capital posture, making direct investments in early-stage biotech companies. The firm's capital base is not publicly disclosed, so the nature of its limited partners, if any, remains unknown.

Outram Bio's mandate is narrowly focused on biotechnology and life sciences. Public information does not indicate the firm evaluates opportunities in consumer technology, fintech, enterprise software, real estate, or other non-healthcare verticals. Its exclusion profile is driven by sector concentration rather than an explicit avoidance list.